1

NanoString Technologies

#10438

Rank

$5.07M

Marketcap

US United States

Country

NanoString Technologies
Leadership team

Mr. R. Bradley Gray (CEO, Pres & Director)

Mr. K. Thomas Bailey M.B.A. (Chief Financial Officer)

Dr. Joseph M. Beechem (Chief Scientific Officer and Sr. VP of R&D)

Products/ Services
Biotechnology, Health Diagnostics, Medical
Number of Employees
500 - 1000
Headquarters
Seattle, Washington, United States
Established
2003
Company Registration
SEC CIK number: 0001401708
Revenue
100M - 500M
Traded as
NSTG
Social Media
Overview
Location
Summary
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
History

NanoString was founded in 2003 to pursue the commercialization of a patented technology invented by Dr. Mark Niedergang, a research scientist at the Fred Hutchinson Cancer Research Center in Seattle, Washington. NanoString’s commercialization efforts were largely successful and its trademarked “nCounter Analysis System” rapidly gained acceptance in both clinical and research laboratories around the world.

Mission
To enable better translational research by using molecular barcodes to tag RNA or DNA for direct, digital detection or quantitation.
Vision
Our vision is to be the global leader in enabling precision healthcare solutions through our advanced technologies.
Key Team

Mr. J. Chad Brown (Sr. Advisor)

Mr. Mark A. Winham (Sr. VP of Operations)

Mr. Douglas S. Farrell (VP of Investor Relations & Corp. Communications)

Ms. Kathryn Surace-Smith (Sr. VP of HR & Legal Affairs and Corp. Sec.)

Mr. David W. Ghesquiere (Sr. VP of Corp. & Bus. Devel.)

Elizabeth Schneider Ph.D. (Sr. Global Marketing Mang.)

Dr. Mary Tedd Allen (Sr. VP of Strategic Initiatives)

Recognition and Awards
NanoString has been honored by Best Workplaces for Innovators by Fast Company Magazine and CogX Best of Tech Awards for COVID-19 Innovation, as well as recognition by Deloitte’s Technology Fast 500 and Inc. Magazine’s Inc. 500 lists.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

NanoString Technologies
Leadership team

Mr. R. Bradley Gray (CEO, Pres & Director)

Mr. K. Thomas Bailey M.B.A. (Chief Financial Officer)

Dr. Joseph M. Beechem (Chief Scientific Officer and Sr. VP of R&D)

Products/ Services
Biotechnology, Health Diagnostics, Medical
Number of Employees
500 - 1000
Headquarters
Seattle, Washington, United States
Established
2003
Company Registration
SEC CIK number: 0001401708
Revenue
100M - 500M
Traded as
NSTG
Social Media